
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics Inc. has demonstrated strong growth in its Pharmacogenomics segment, with a 14% year-over-year increase in 2024, highlighting the robust demand for their GeneSight product, which experienced a 23% growth during the same period. The prenatal testing segment, particularly Prequel and Foresight tests, also showed positive momentum with a combined 12% growth in 4Q24 and 17% growth for the full fiscal year 2024, indicating strong market demand that is expected to accelerate in 2025. Furthermore, the anticipated launch of an expanded hereditary cancer screening test in the latter half of 2025, along with potential regulatory benefits from updates in carrier screening guidelines, positions Myriad Genetics to capitalize on sustainable growth and capture additional market share in a consolidating market.
Bears say
Myriad Genetics has faced significant challenges leading to a negative outlook, primarily highlighted by the recent loss of a private payer's reimbursement for GeneSight and changes in NCCN guideline language, which have negatively impacted near-term revenues. The company’s FY25 revenue guidance of $840M-$860M falls short of both analyst and consensus expectations, further raising concerns about its ability to accelerate organic growth and maintain relationships with payors, which are critical for its operational performance. Additionally, ongoing risks such as regulatory challenges, competition, and the potential for continued price erosion could impede future profitability and market share gains, suggesting that Myriad Genetics may struggle to meet revised expectations set by previous leadership.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares